You Position: Home > Paper
Signal transduction by protein tyrosine kinases and antitumor agents
( views:783, downloads:412 )
- Author:
- No author available
- Journal Title:
- ACTA PHARMACEUTICA SINICA
- Issue:
- 4
- DOI:
- 10.3321/j.issn:0513-4870.2008.04.001
- Key Word:
- 信号转导;受体酪氨酸激酶;非受体酪氨酸激酶;酪氨酸激酶抑制剂;抗肿瘤药物
Abstract： 细胞信号转导(signal transduction)在细胞的代谢、分裂、分化、生物功能及死亡过程中起着重要作用,肿瘤的发生和发展与细胞信号转导过度激活有关.本文简要阐述了蛋白酪氨酸激酶(protein tyrosine kinases,PTKs)介导的信号转导途径,分别介绍了受体酪氨酸激酶介导的Ras/Raf/MAPK和PI-3K/Akt途径,非受体酪氨酸激酶介导的Src、Bcr-Abl和JAK/STAT途径.以此5条信号转导通路中参与的重要蛋白分子为靶点,统计和介绍了相关的已经上市或处于临床研究的抗肿瘤药物.
- [1]朱孝峰,刘宗潮,曾益新.酪氨酸激酶受体的信号转导途径与肿瘤治疗[J].2002,(3).
- [2]郑合勇,胡建达,郑志宏,等.大黄素可能通过抑制Akt信号通路诱导HL-60细胞凋亡[J].2007,(11).
- [3]邓小强,向明礼,贾若,等.选择性的激酶ATP竞争性抑制剂设计研究进展[J].2007,(12).
- [4]Igor, Vivanco,Charles L, Sawyers.The phosphatidylinositol 3-Kinase AKT pathway in human cancer.[J].2002,2(7).
- [5]Murray PJ.The JAK-STAT signaling pathway: input and output integration.[J].2007,178(5).
- [6]Harousseau JL.Farnesyltransferase inihibitors in hematologic malignancies.[J].2007,21(4).
- [7]Manetti F,Botta M,Schenone S.SRC inhibitors and angiogenesis.[J].2007,13(21).
- [8]Margaret, von Mehren.Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.[J].2006,6 Suppl 1.
- [9]von-Mehren M,Mackenzie AR.Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future.[J].2007,7(8).
- [10]Kohno M,Pouyssegur J.Targeting the ERK signaling pathway in cancer therapy.[J].2006,38(3).
- [11]Buolamwini JK,Kamath S.Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development.[J].2006,26(5).
- [12]Jain RK,Willett CG,Duda DG.Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.[J].2007,25(26).
- [13]Schenone S,Bondavalli F,Botta M.Antiangiogenic agents: an update on small molecule VEGFR inhibitors.[J].2007,14(23).
- [14]Billi AM,Blalock WL,Cocco L,etc.Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.[J].2007,14(19).
- [15]Ishitsuka K,Yasui H,Hamasaki M,etc.Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.[J].2005,19(7).
- [16]Beverly E, Barton,James G, Karras,Thomas F, Murphy,etc.Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines.[J].2004,3(1).
- [17]Ganser A,Herrmann TR,Morgan MA,etc.Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma.[J].2007,25(1).
- [18]Lewis RS,Stephenson SE,Ward AC,etc.Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.[J].2007,44(10).
- [19]Shaw RJ,Cantley LC.Ras, PI(3)K and mTOR signalling controls tumour cell growth[J].2006,441(7092).
- [20]Cowan-Jacob SW,Hochhaus A,Weisberg E,etc.Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.[J].2007,7(5).
- [21]Wu BQ,Lucas J,Boschelli DH,etc.Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles[J].2006,49(26).
- [22]English JM,Sebolt-Leopold JS.Mechanisms of drug inhibition of signalling molecules[J].2006,441(7092).
- [23]Schenone S,Manetti F,Botta M.Last findings on dual inhibitors of abl and SRC tyrosine-kinases.[J].2007,7(2).
- [24]Koutsoukos A,Kurzrock R,Sun YN,etc.Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.[J].2007,25(17).